Parasight System Inc. has developed and manufactures a veterinary diagnostic analyzer that combines antigen-based fluorescence detection with advanced AI-powered image recognition technology, delivering highly accurate and efficient analysis for a variety of diagnostic tests and different medium, including fecal, heartworm, and Lyme disease tests in veterinary practices.
Parasight System Inc. aims to address the inefficiencies and inaccuracies in traditional veterinary diagnostic methods. Current approaches to fecal exams, heartworm detection, and Lyme disease testing often rely on manual processes that are time-consuming, prone to error, and dependent on subjective interpretation. This can lead to missed diagnoses or delayed treatments, ultimately affecting the health and well-being of animals. Parasight System's solution leverages advanced AI technology and antigen-based fluorescence detection to automate and enhance diagnostic accuracy. By providing results that are 4 to 10 times more precise than traditional methods, Parasight empowers veterinarians to make faster, more confident decisions. This not only improves patient outcomes but also streamlines clinic operations, saving valuable time and resources for veterinary professionals.
Parasight System Inc. is driven by a cohesive team combines industry knowledge, technical expertise, and a passion for improving veterinary diagnostics to drive Parasight System’s success and ongoing innovation.
Eric Hauck, CEO/Co-Founder: A visionary leader with a proven track record in bringing advanced diagnostic solutions to market, driving strategic growth, and fostering industry partnerships.
Dr. Paul Slusarewicz, Chief Scientific Officer: Leads the research and validation efforts, ensuring the scientific rigor behind Parasight's groundbreaking diagnostic solutions. Additional he oversees the development and refinement of Parasight’s proprietary AI technologies, leveraging extensive expertise in machine learning and diagnostic innovation.
Sam Razor, Executive Chairman: Focuses on building strong customer relationships and expanding Parasight’s reach through strategic partnerships and industry engagement.
Ryan Kurz, Director of Manufacturing: Ensures the scalability and quality of production to meet growing market demand, optimizing manufacturing processes for efficiency and reliability.
Our go to market strategy is primarily focused on strategic partnerships, including a distribution agreement with Midwest Veterinary Supply, collaborations with group purchasing organizations, and working with reference labs like Affordable Pet Labs, have further validated the technology and expanded its market presence. Looking ahead, Parasight is focused on refining its AI algorithms, enhancing its diagnostic offerings, and expanding integrations with cloud-based veterinary practice management systems, ensuring accessibility and scalability.
Parasight System Inc. generates revenue through a combination of diagnostic analyzer sales, recurring consumable sales, and service agreements. Here’s an overview of its revenue streams:
- Diagnostic Analyzer Sales: Clinics and veterinary practices purchase the Parasight analyzer, which serves as the cornerstone of their diagnostic capabilities.
- Consumable Sales: The analyzer relies on proprietary test kits and reagents for its operation. These consumables, which are required for each diagnostic test, create a recurring revenue model as practices regularly reorder supplies.
- Service and Maintenance Contracts: Parasight offers service agreements to ensure analyzer functionality and performance, providing an additional steady revenue stream while enhancing customer satisfaction and loyalty.
- Partnership Agreements: Revenue may also be generated through strategic collaborations with organizations, leveraging distribution and diagnostic partnerships.
- Expansion of Test Offerings: With the introduction of FlowsightAI™ and HemasightAI™, Parasight is poised to capture additional revenue by offering an expanded suite of diagnostic tests, increasing the volume of consumable use per practice. This hybrid model combines one-time hardware sales with ongoing revenue from consumables and services, creating a scalable and sustainable business model.
We are raising $10 million dollars to secure a stable & durable supply chain, fulfill orders & scale production to ISO-9002-certified contract manufacturers, increase the velocity of expanding new test development, and to scale the sales and marketing presence.
Parasight System Inc. is revolutionizing veterinary diagnostics with its advanced analyzer, which integrates antigen-based fluorescence detection and AI-powered technology to deliver results 4 to 10 times more accurate than traditional methods. Supported by 8 issued U.S. patents and 14 peer-reviewed studies, the system has gained the trust of nearly 500 veterinary practices.
In addition to its proven fecal diagnostic capabilities, Parasight has recently introduced FlowsightAI™ and HemasightAI™, expanding the analyzer's functionality to include testing for heartworm, Lyme disease, giardia, and a wide range of other pathogens. These advancements enable comprehensive analysis of fecal, mucus, and blood samples, detecting parasites like hookworms, roundworms, and whipworms, as well as diseases caused by viruses, bacteria, and protozoa. This expanded test menu reduces the need for multiple diagnostic machines, streamlining workflows while enhancing precision and efficiency for veterinary practices.
We have received grants and raised venture capital to fund the develop and production of our technology.
